My WebLink
|
Help
|
About
|
Sign Out
Home
Browse
Search
2024_OpioidSettlemtAgrmt_JanssenJJ
>
Meetings
>
2024
>
04. April
>
2024-04-16 10:00 AM - Commissioners' Agenda
>
2024_OpioidSettlemtAgrmt_JanssenJJ
Metadata
Thumbnails
Annotations
Entry Properties
Last modified
4/11/2024 1:10:33 PM
Creation date
4/11/2024 1:08:48 PM
Metadata
Fields
Template:
Meeting
Date
4/16/2024
Meeting title
Commissioners' Agenda
Location
Commissioners' Auditorium
Address
205 West 5th Room 109 - Ellensburg
Meeting type
Regular
Meeting document type
Supporting documentation
Supplemental fields
Item
Request to Approve a Resolution Accepting the Johnson & Johnson (Janssen) Washington State State-Wide Opioid Settlement Agreement
Order
7
Placement
Consent Agenda
Row ID
116716
Type
Agreement
There are no annotations on this page.
Document management portal powered by Laserfiche WebLink 9 © 1998-2015
Laserfiche.
All rights reserved.
/
127
PDF
Print
Pages to print
Enter page numbers and/or page ranges separated by commas. For example, 1,3,5-12.
After downloading, print the document using a PDF reader (e.g. Adobe Reader).
View images
View plain text
<br />J-11 <br /> <br /> <br />3. Enable states to use PDMP data in support of surveillance or intervention <br />strategies, including MAT referrals and follow-up for individuals identified <br />within PDMP data as likely to experience OUD in a manner that complies <br />with all relevant privacy and security laws and rules. <br />6. Ensuring PDMPs incorporate available overdose/naloxone deployment data, <br />including the United States Department of Transportation’s Emergency Medical <br />Technician overdose database in a manner that complies with all relevant privacy and <br />security laws and rules. <br />7. Increasing electronic prescribing to prevent diversion or forgery. <br />8. Educating dispensers on appropriate opioid dispensing. <br />G. PREVENT MISUSE OF OPIOIDS <br />Support efforts to discourage or prevent misuse of opioids through evidence-based or <br />evidence-informed programs or strategies that may include, but are not limited to, the <br />following: <br />1. Funding media campaigns to prevent opioid misuse. <br />2. Corrective advertising or affirmative public education campaigns based on evidence. <br />3. Public education relating to drug disposal. <br />4. Drug take-back disposal or destruction programs. <br />5. Funding community anti-drug coalitions that engage in drug prevention efforts. <br />6. Supporting community coalitions in implementing evidence-informed prevention, <br />such as reduced social access and physical access, stigma reduction—including <br />staffing, educational campaigns, support for people in treatment or recovery, or <br />training of coalitions in evidence-informed implementation, including the Strategic <br />Prevention Framework developed by the U.S. Substance Abuse and Mental Health <br />Services Administration (“SAMHSA”). <br />7. Engaging non-profits and faith-based communities as systems to support prevention. <br />8. Funding evidence-based prevention programs in schools or evidence-informed school <br />and community education programs and campaigns for students, families, school <br />employees, school athletic programs, parent-teacher and student associations, and <br />others. <br />9. School-based or youth-focused programs or strategies that have demonstrated <br />effectiveness in preventing drug misuse and seem likely to be effective in preventing <br />the uptake and use of opioids.
The URL can be used to link to this page
Your browser does not support the video tag.